Most molecular-targeted cancer therapies show no 'substantial' benefit at approval healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
The conventional way of classifying metastatic cancers according to their organ of origin is denying people access to drugs that could help them. The conventional way of classifying metastatic cancers according to their organ of origin is denying people access to drugs that could help them.
Nearly half of oncology drugs approved since 1998 are precision therapies medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Tissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression on frontline atezolizumab and bevacizumab to targeted therapy or another TKI based on identified genomic alterations.
Patients with cancer are increasingly having tumor DNA sequenced to identify disease markers and potential targets, but some investigators question whether every cancer patient can benefit.